Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Combating food allergies with vaccine viruses

31.07.2013
Researchers of the Paul-Ehrlich-Institut have succeeded in preventing food allergy against chicken protein using a modified vaccine virus.

The viruses serve a dual function: They transfer genetic information of the allergen into the target cell of the immune system and they have an inherent immunomodulatory effect. The research results have been published in the online edition of the journal Allergy of 30 July 2013 (DOI 10.1111/all.12192)


Inflammation of intestinal mucosa in allergic mice (on the left; e.g. thickened basal layer) as compared to MVA-OVA-vaccinated mice with unimpaired intestinal mucosa (on the right side).
Paul-Ehrlich-Institut

Food allergies are on the increase in all industrialised countries, affecting around five per cent of all children and four per cent of all adults. Allergen avoidance is currently the only established treatment of choice. Specific immunotherapy using allergen extracts, which is common in the treatment of pollen allergies, has not yet been established for food allergies. Moreover, there is an inherent risk of serious adverse reactions including anaphylactic shock.

Researchers of the Paul-Ehrlich-Institut have therefore taken a completely novel approach towards immunotherapy of food allergy, which is based on modified vaccinia virus Ankara (MVA). MVA is a modified vaccine virus which has been found to be safe in several clinical trials in infection medicine. MVA facilitates transfer of the genetic information of the allergen to antigen presenting cells of the body. Cells infected with the virus begin to produce the allergen and present it to the immune system. Unlike the established immunotherapy of pollen or house dust mite allergy where allergen extracts are applied directly, the new method ascertains that the immune system does not come into contact with the allergen before allergen fragments are presented on the surface of antigen presenting cells. Serious allergic reactions as in the case of direct allergen uptake via food consumption can be ruled out.

Researchers in the Allergology and Virology Divisions at the Paul-Ehrlich-Institut had already been able to show that "vaccination" of mice with MVA carrying the gene for the chicken protein ovalbumin (MVA-OVA) prevented the usually considerable increase in allergy inducing IgE antibodies in response to exposure to the allergen [1].

Which clinical significance do these changes imply? To establish this, Dr Masako Toda, head of the Temporary Research Group "Experimental Allergy Models" at the PEI, and her co-workers developed a model of intestinal food allergy in mice. Sensitisation of mice to ovalbumin led to clinical symptoms such as diarrhoea, loss of bodyweight, and drop of body temperature. The researchers of the PEI were able to show that allergic symptoms could be prevented by vaccination with MVA-OVA and, what’s more, in collaboration with researchers of Tokyo University, Japan, they were able to establish that the vaccination could prevent inflammatory changes of the intestinal mucosa (see figure).

When examining the local immune response in the small intestine, the researchers were also able to prove – based on the modified release of the cytokines (inhibition of interleukin-4 and stimulation of interferon-gamma release) – that the adverse (allergic) response of TH2 helper cells was inhibited and the desired TH1 helper cell response was stimulated. ""This is the very result we wish to see in treating an allergy: the suppression of IgE and an increase in TH1 response"", Dr Stephan Scheurer explained the success of this approach. Dr Scheurer is the head of the Section "Recombinant Allergen Therapeutics" at the PEI.

The next steps to be taken by the researchers of the PEI will be to test how long this allergy protection will last and whether the therapy approach can be used to treat fully established allergies. ""If this is possible for our model allergen ovalbumin, we assume that the model can also be transferred to other food allergens"", explained Dr Scheurer.

Background

An allergy involves an excessive TH2 helper cell response. TH2 helper cells are a specialised group of lymphocytes of the immune system. During an allergic reaction, these cells respond to usually harmless antigens such as pollen, but also antigens in peanuts, hen's eggs, etc. Specific immunotherapy intends to re-establish the immune balance in favour of a TH1 helper response. In the above-described novel approach of immunotherapy, the modified virus Ankara not only serves as a transport vehicle of genetic information of the allergen but is also an effective immune modulator, since it creates a strong TH1 helper cell response against antigens. This process involves induction of allergen specific IgG2a antibodies, which can act as blocking antibodies, as well as cytokines (interferon-gamma) which counteract allergic reactions. This helps to restore a normal immune response.

Literature

[1] Albrecht M, Suezer Y, Staib C, Sutter G, Vieths S, Reese G (2008): Vaccination with a Modified Vaccinia Virus Ankara-based vaccine protects mice from allergic sensitization. J Gene Med 10: 1324-1333. Online-Abstract.

Original publication

Bohnen C, Wangorsch A, Schülke S, Nakajima-Adachi H, Hachimura S, Burggraf M, Süzer Y, Schwantes A, Sutter G, Waibler Z, Reese G, Toda M, Scheurer S, Vieths S (2013): Vaccination with recombinant modified vaccinia virus1 Ankara prevents the onset of intestinal allergy in mice.

Allergy Jul 30 [Epub ahead of print].

Weitere Informationen:

http://onlinelibrary.wiley.com/doi/10.1111/all.12192/abstract
- Publications Abstract
http://www.ncbi.nlm.nih.gov/pubmed/18816482?ordinalpos=60&itool=EntrezSystem2.
PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum
Abstract of J Gene Med-Paper
http://www.pei.de/EN/information/journalists-press/press-releases/2013/03-combating-food-allergies-with-vaccine-viruses.html

Press release on PEI-Website

Dr. Susanne Stöcker | idw
Further information:
http://www.pei.de/

More articles from Life Sciences:

nachricht Newly designed molecule binds nitrogen
23.02.2018 | Julius-Maximilians-Universität Würzburg

nachricht Atomic Design by Water
23.02.2018 | Max-Planck-Institut für Eisenforschung GmbH

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Attoseconds break into atomic interior

A newly developed laser technology has enabled physicists in the Laboratory for Attosecond Physics (jointly run by LMU Munich and the Max Planck Institute of Quantum Optics) to generate attosecond bursts of high-energy photons of unprecedented intensity. This has made it possible to observe the interaction of multiple photons in a single such pulse with electrons in the inner orbital shell of an atom.

In order to observe the ultrafast electron motion in the inner shells of atoms with short light pulses, the pulses must not only be ultrashort, but very...

Im Focus: Good vibrations feel the force

A group of researchers led by Andrea Cavalleri at the Max Planck Institute for Structure and Dynamics of Matter (MPSD) in Hamburg has demonstrated a new method enabling precise measurements of the interatomic forces that hold crystalline solids together. The paper Probing the Interatomic Potential of Solids by Strong-Field Nonlinear Phononics, published online in Nature, explains how a terahertz-frequency laser pulse can drive very large deformations of the crystal.

By measuring the highly unusual atomic trajectories under extreme electromagnetic transients, the MPSD group could reconstruct how rigid the atomic bonds are...

Im Focus: Developing reliable quantum computers

International research team makes important step on the path to solving certification problems

Quantum computers may one day solve algorithmic problems which even the biggest supercomputers today can’t manage. But how do you test a quantum computer to...

Im Focus: In best circles: First integrated circuit from self-assembled polymer

For the first time, a team of researchers at the Max-Planck Institute (MPI) for Polymer Research in Mainz, Germany, has succeeded in making an integrated circuit (IC) from just a monolayer of a semiconducting polymer via a bottom-up, self-assembly approach.

In the self-assembly process, the semiconducting polymer arranges itself into an ordered monolayer in a transistor. The transistors are binary switches used...

Im Focus: Demonstration of a single molecule piezoelectric effect

Breakthrough provides a new concept of the design of molecular motors, sensors and electricity generators at nanoscale

Researchers from the Institute of Organic Chemistry and Biochemistry of the CAS (IOCB Prague), Institute of Physics of the CAS (IP CAS) and Palacký University...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

2nd International Conference on High Temperature Shape Memory Alloys (HTSMAs)

15.02.2018 | Event News

Aachen DC Grid Summit 2018

13.02.2018 | Event News

How Global Climate Policy Can Learn from the Energy Transition

12.02.2018 | Event News

 
Latest News

Basque researchers turn light upside down

23.02.2018 | Physics and Astronomy

Finnish research group discovers a new immune system regulator

23.02.2018 | Health and Medicine

Attoseconds break into atomic interior

23.02.2018 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>